Literature DB >> 10919974

Inflammation and infection in naive human cystic fibrosis airway grafts.

R Tirouvanziam1, S de Bentzmann, C Hubeau, J Hinnrasky, J Jacquot, B Péault, E Puchelle.   

Abstract

Exacerbated inflammation is now recognized as an important component of cystic fibrosis (CF) airway disease. Whether inflammation is part of the basic defect in CF or a response to persistent infection remains controversial. We addressed this question using human fetal tracheal grafts in severe combined immunodeficient mice. This model yields histologically mature, and most importantly, naive CF and non-CF surrogate airways. Significant inflammatory imbalance was found in naive CF airway grafts, including a highly increased intraluminal interleukin 8 content (CF: 10.1 +/- 2.2 ng/ml; non-CF: 1.2 +/- 0.6 ng/ml; P < 0.05) and consistent accumulation of leukocytes in the subepithelial region (P < 0.001). CF airway grafts were not histologically affected until challenged with Pseudomonas aeruginosa, which provoked: (1) early (before 3 h) and massive leukocyte transepithelial migration, (2) intense epithelial exfoliation, and (3) rapid progression of bacteria toward the lamina propria. In non-CF grafts, these three sets of events were not observed before 6 h. Using a model of naive human airways, we thus demonstrate that before any infection, CF airways are in a proinflammatory state. After infection, the basal inflammatory imbalance contributes to exert severe damage to the mucosa, paving the way for bacterial colonization and subsequent steps of CF airway disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919974     DOI: 10.1165/ajrcmb.23.2.4214

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  71 in total

1.  Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa.

Authors:  C Hubeau; M Lorenzato; J P Couetil; D Hubert; D Dusser; E Puchelle; D Gaillard
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.

Authors:  R B Moss
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

3.  Pediatric Respiratory Assembly. Mini symposium on lung inflammation.

Authors:  Larry C Lands; A Keith Tanswell; Sophie Laberge; Christine McCusker; Felix Ratjen
Journal:  Can Respir J       Date:  2010 Mar-Apr       Impact factor: 2.409

Review 4.  New insights into pulmonary inflammation in cystic fibrosis.

Authors:  S Rao; J Grigg
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

5.  Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8.

Authors:  Sharmistha Bhattacharyya; Nagaraja S Balakathiresan; Clifton Dalgard; Usha Gutti; David Armistead; Cathy Jozwik; Meera Srivastava; Harvey B Pollard; Roopa Biswas
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

6.  Role of CD95 in pulmonary inflammation and infection in cystic fibrosis.

Authors:  Katrin Anne Becker; Brian Henry; Regan Ziobro; Burkhard Tümmler; Erich Gulbins; Heike Grassmé
Journal:  J Mol Med (Berl)       Date:  2012-09       Impact factor: 4.599

Review 7.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 8.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

9.  Ceramide mediates lung fibrosis in cystic fibrosis.

Authors:  Regan Ziobro; Brian Henry; Michael J Edwards; Alex B Lentsch; Erich Gulbins
Journal:  Biochem Biophys Res Commun       Date:  2013-03-21       Impact factor: 3.575

10.  High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

Authors:  Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.